| Bioactivity | LY2623091 is a mineralocorticoid receptor antagonist for the treatment of refractory hypertension. LY2623091 exhibits CYP3A4-dependent clearance and synergistic effects with CYP3A4 inhibitors[1][2]. |
| CAS | 1162264-07-4 |
| Formula | C30H30FN5O3 |
| Molar Mass | 527.59 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dickinson G L, et al. Physiologically based pharmacokinetic modeling to understand the observed drug–drug interaction of LY2623091 with CYP3A inhibitors itraconazole and diltiazem[J]. International journal of Pharmacokinetics, 2017, 2(4): 233-245. [2]. Kocienski P. Synthesis of LY2623091[J]. Synfacts, 2017, 13(05): 0451. |
LY2623091
CAS: 1162264-07-4 F: C30H30FN5O3 W: 527.59
LY2623091 is a mineralocorticoid receptor antagonist for the treatment of refractory hypertension. LY2623091 exhibits CY
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.